![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CYP4F11 |
Gene summary for CYP4F11 |
![]() |
Gene information | Species | Human | Gene symbol | CYP4F11 | Gene ID | 57834 |
Gene name | cytochrome P450 family 4 subfamily F member 11 | |
Gene Alias | CYPIVF11 | |
Cytomap | 19p13.12 | |
Gene Type | protein-coding | GO ID | GO:0001676 | UniProtAcc | Q9HBI6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57834 | CYP4F11 | LZE2D | Human | Esophagus | HGIN | 3.64e-03 | 5.76e-01 | 0.0642 |
57834 | CYP4F11 | LZE2T | Human | Esophagus | ESCC | 5.44e-10 | 1.09e+00 | 0.082 |
57834 | CYP4F11 | LZE4T | Human | Esophagus | ESCC | 9.53e-29 | 8.65e-01 | 0.0811 |
57834 | CYP4F11 | LZE7T | Human | Esophagus | ESCC | 2.56e-05 | 2.92e-01 | 0.0667 |
57834 | CYP4F11 | LZE22T | Human | Esophagus | ESCC | 1.57e-03 | 2.71e-01 | 0.068 |
57834 | CYP4F11 | LZE24T | Human | Esophagus | ESCC | 9.19e-06 | 1.55e-01 | 0.0596 |
57834 | CYP4F11 | LZE21T | Human | Esophagus | ESCC | 1.57e-07 | 3.78e-01 | 0.0655 |
57834 | CYP4F11 | P1T-E | Human | Esophagus | ESCC | 4.62e-03 | 1.56e-01 | 0.0875 |
57834 | CYP4F11 | P4T-E | Human | Esophagus | ESCC | 1.75e-05 | 1.67e-01 | 0.1323 |
57834 | CYP4F11 | P9T-E | Human | Esophagus | ESCC | 3.99e-67 | 1.53e+00 | 0.1131 |
57834 | CYP4F11 | P10T-E | Human | Esophagus | ESCC | 7.92e-69 | 1.09e+00 | 0.116 |
57834 | CYP4F11 | P12T-E | Human | Esophagus | ESCC | 9.53e-09 | 3.34e-01 | 0.1122 |
57834 | CYP4F11 | P15T-E | Human | Esophagus | ESCC | 6.36e-56 | 1.53e+00 | 0.1149 |
57834 | CYP4F11 | P20T-E | Human | Esophagus | ESCC | 8.24e-04 | 1.05e-01 | 0.1124 |
57834 | CYP4F11 | P21T-E | Human | Esophagus | ESCC | 6.56e-15 | 3.41e-01 | 0.1617 |
57834 | CYP4F11 | P22T-E | Human | Esophagus | ESCC | 3.87e-34 | 6.29e-01 | 0.1236 |
57834 | CYP4F11 | P27T-E | Human | Esophagus | ESCC | 8.40e-04 | 1.20e-01 | 0.1055 |
57834 | CYP4F11 | P28T-E | Human | Esophagus | ESCC | 2.93e-15 | 4.02e-01 | 0.1149 |
57834 | CYP4F11 | P30T-E | Human | Esophagus | ESCC | 1.82e-53 | 2.33e+00 | 0.137 |
57834 | CYP4F11 | P31T-E | Human | Esophagus | ESCC | 2.13e-27 | 5.44e-01 | 0.1251 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19016614 | Esophagus | HGIN | quinone metabolic process | 13/2587 | 40/18723 | 2.04e-03 | 2.13e-02 | 13 |
GO:190166112 | Esophagus | ESCC | quinone metabolic process | 34/8552 | 40/18723 | 3.00e-07 | 4.27e-06 | 34 |
GO:004206027 | Esophagus | ESCC | wound healing | 243/8552 | 422/18723 | 4.62e-07 | 6.25e-06 | 243 |
GO:00066318 | Esophagus | ESCC | fatty acid metabolic process | 217/8552 | 390/18723 | 4.21e-05 | 3.39e-04 | 217 |
GO:00463948 | Esophagus | ESCC | carboxylic acid biosynthetic process | 175/8552 | 314/18723 | 1.98e-04 | 1.26e-03 | 175 |
GO:00067661 | Esophagus | ESCC | vitamin metabolic process | 67/8552 | 106/18723 | 2.03e-04 | 1.28e-03 | 67 |
GO:00160538 | Esophagus | ESCC | organic acid biosynthetic process | 175/8552 | 316/18723 | 3.04e-04 | 1.82e-03 | 175 |
GO:00723297 | Esophagus | ESCC | monocarboxylic acid catabolic process | 74/8552 | 122/18723 | 6.03e-04 | 3.27e-03 | 74 |
GO:00421805 | Esophagus | ESCC | cellular ketone metabolic process | 120/8552 | 211/18723 | 6.70e-04 | 3.55e-03 | 120 |
GO:00442827 | Esophagus | ESCC | small molecule catabolic process | 201/8552 | 376/18723 | 1.35e-03 | 6.41e-03 | 201 |
GO:00160427 | Esophagus | ESCC | lipid catabolic process | 168/8552 | 320/18723 | 7.97e-03 | 2.84e-02 | 168 |
GO:004206020 | Oral cavity | OSCC | wound healing | 237/7305 | 422/18723 | 4.51e-13 | 2.18e-11 | 237 |
GO:19016613 | Oral cavity | OSCC | quinone metabolic process | 32/7305 | 40/18723 | 1.40e-07 | 2.34e-06 | 32 |
GO:00421804 | Oral cavity | OSCC | cellular ketone metabolic process | 111/7305 | 211/18723 | 3.94e-05 | 3.45e-04 | 111 |
GO:00160537 | Oral cavity | OSCC | organic acid biosynthetic process | 155/7305 | 316/18723 | 1.64e-04 | 1.13e-03 | 155 |
GO:00463947 | Oral cavity | OSCC | carboxylic acid biosynthetic process | 154/7305 | 314/18723 | 1.73e-04 | 1.19e-03 | 154 |
GO:00066317 | Oral cavity | OSCC | fatty acid metabolic process | 186/7305 | 390/18723 | 2.65e-04 | 1.69e-03 | 186 |
GO:00723296 | Oral cavity | OSCC | monocarboxylic acid catabolic process | 66/7305 | 122/18723 | 5.02e-04 | 2.95e-03 | 66 |
GO:005087819 | Oral cavity | OSCC | regulation of body fluid levels | 179/7305 | 379/18723 | 6.19e-04 | 3.50e-03 | 179 |
GO:00442826 | Oral cavity | OSCC | small molecule catabolic process | 174/7305 | 376/18723 | 2.25e-03 | 1.00e-02 | 174 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CYP4F11 | SNV | Missense_Mutation | rs142657300 | c.443G>A | p.Arg148His | p.R148H | Q9HBI6 | protein_coding | deleterious(0.01) | probably_damaging(0.96) | TCGA-EC-A24G-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CYP4F11 | SNV | Missense_Mutation | rs771046979 | c.770N>A | p.Arg257His | p.R257H | Q9HBI6 | protein_coding | tolerated(0.13) | benign(0.036) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CYP4F11 | SNV | Missense_Mutation | c.1321N>A | p.Asp441Asn | p.D441N | Q9HBI6 | protein_coding | tolerated(0.4) | benign(0.123) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CYP4F11 | SNV | Missense_Mutation | novel | c.1232N>A | p.Gly411Asp | p.G411D | Q9HBI6 | protein_coding | deleterious(0.03) | possibly_damaging(0.521) | TCGA-EY-A1GU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CYP4F11 | SNV | Missense_Mutation | rs201156268 | c.1420N>A | p.Ala474Thr | p.A474T | Q9HBI6 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
CYP4F11 | SNV | Missense_Mutation | novel | c.14N>A | p.Ser5Asn | p.S5N | Q9HBI6 | protein_coding | tolerated(0.12) | benign(0.013) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
CYP4F11 | SNV | Missense_Mutation | novel | c.594N>T | p.Met198Ile | p.M198I | Q9HBI6 | protein_coding | deleterious(0) | possibly_damaging(0.619) | TCGA-50-6673-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CYP4F11 | SNV | Missense_Mutation | c.1129N>A | p.Gln377Lys | p.Q377K | Q9HBI6 | protein_coding | tolerated(0.52) | benign(0.031) | TCGA-55-7227-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | carboplatin | SD | |
CYP4F11 | SNV | Missense_Mutation | rs201684723 | c.1169N>A | p.Arg390Gln | p.R390Q | Q9HBI6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-99-8025-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | gemzar | SD |
CYP4F11 | SNV | Missense_Mutation | c.857N>C | p.Phe286Ser | p.F286S | Q9HBI6 | protein_coding | tolerated(0.12) | benign(0.038) | TCGA-39-5019-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
57834 | CYP4F11 | DRUGGABLE GENOME, ENZYME, CYTOCHROME P450 | warfarin | WARFARIN | 28620303 |
Page: 1 |